Intervention in gastro-enteropancreatic neuroendocrine tumours

详细信息    查看全文

• 作者：Eric Baudin ; MD ; PhD^a ; ^{baudin@igr.fr} ; ^{eric.baudin@igr.fr} (Head of the Endocrine Oncology Unit) ; David Planchard ; MD ; PhD^b ; ^{david.planchard@igr.fr} (Thoracic Oncologist) ; Jean-Yves Scoazec ; MD ; PhD^c ; ^{jean-yves.scoazec@igr.fr} (Head of the Translational Research Department) ; Joë ; l Guigay ; MD ; PhD^b ; ^{joel.guigay@igr.fr} (Professor of Medicine ; Head ; Neck Department) ; Clarisse Dromain ; MD^d ; ^{clarisse.dromain@igr.fr} (Head of the Radiology Department) ; Julien Hadoux ; MD^a ; ^{jhadoux@gmail.com} (Fellow) ; Thierry Debaere ; MD ; PhD^d ; ^{thierry.debaere@igr.fr} (Head of the Interventional Radiology Unit) ; Dominique Elias ; MD ; PhD^e ; ^{dominique.elias@igr.fr} (Head of the Oncology Surgical Department) ; Michel Ducreux ; MD ; PhD^b ; ^{michel.ducreux@igr.f} (Executive Medical Director)
• 关键词：Intervention ; Neuroendocrine tumour ; Neuroendocrine carcinoma ; Well differentiated NET ; Poorly differentiated NET ; Prognosis ; Functioning neuroendocrine tumour ; WHO classification ; Grading ; TNM classification
• 刊名：Best Practice Research Clinical Gastroenterology
• 出版年：2012
• 出版时间：December, 2012
• 年：2012
• 卷：26
• 期：6
• 页码：855-865
• 全文大小：216 K

文摘

Neuroendocrine tumours require dedicated interventions to control their capacity to secrete hormones but also, antitumour growth strategies. Recommendations for early interventions in NET include the management of hormone-related symptoms and poorly differentiated neuroendocrine carcinomas. In contrast, prognostic heterogeneity is a key feature of well differentiated NET that complexified the antitumour strategy whatever the stage in this subgroup of tumour. In this review, timely therapeutic interventions to control hormone-related symptoms and tumour growth in GEP NET patients are discussed. The necessity of controlling hormone-related symptoms as the first step of any strategy affects also the tumour growth control strategy. In the absence of cure at the metastatic stage, progresses are expected in the recognition of well differentiated NET subgroups that display either excellent or poor prognosis.